IONS Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 19%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Biogen, Inc.'s return on equity of 9.36%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $85.47, signalling upside risk potential of 4.43%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.1%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.296, which suggesting that the stock is 70.45% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.93x versus 2.74x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 31.72%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Eli Lilly & Co.'s return on equity of 106.26%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $85.47, signalling upside risk potential of 4.43%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Ionis Pharmaceuticals, Inc. has a beta of 0.296, which suggesting that the stock is 70.45% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.93x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 33.68%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $85.47, signalling upside risk potential of 4.43%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.296, which suggesting that the stock is 70.45% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.93x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 21.32%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Pfizer Inc.'s return on equity of 10.84%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $85.47, signalling upside risk potential of 4.43%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.296, which suggesting that the stock is 70.45% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.93x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.